Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 2/20 | 0.45 |
| ▸ | MMP2 | P08253 | 2/20 | 0.45 |
| ▸ | MMP9 | P14780 | 2/20 | 0.45 |
| ▸ | MMP8 | P22894 | 2/20 | 0.45 |
| ▸ | MMP13 | P45452 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | PPIA | P62937 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.39 |
| ▸ | RELA | Q04206 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31235870 | 1.00 | MMP1 (0.45) | MMP1MMP2MMP9MMP8MMP13 | |
| SCHEMBL23607710 | 0.86 | PPIA (0.48) | MAPTKMT2AMEN1CYP19A1LMNA | |
| SCHEMBL31235875 | 0.83 | PARP1 (0.36) | MMP1MMP2MMP9MMP8MMP13 | |
| SCHEMBL21792429 | 0.83 | PARP1 (0.36) | MMP1MMP2MMP9MMP8MMP13 | |
| SCHEMBL23607717 | 0.81 | PPIA (0.48) | MAPTKMT2AMEN1CYP19A1LMNA | |
| SCHEMBL28383031 | 0.79 | MAPT (0.45) | MMP1MMP2MMP9MMP8MMP13 | |
| SCHEMBL23607702 | 0.78 | PPIA (0.50) | MAPTKMT2AMEN1CYP19A1LMNA | |
| SCHEMBL15831277 | 0.77 | MEN1 (0.66) | MMP1MMP2MMP9MMP8MMP13 | |
| SCHEMBL23607716 | 0.77 | PPIA (0.48) | MAPTKMT2AMEN1CYP19A1LMNA | |
| SCHEMBL21792428 | 0.76 | HDAC1 (0.49) | KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210205464-A1 | Linker Containing Arylnitro, Antibody-Drug Conjugate Containing Linker and Use of Linker | ZHEJIANG YANGSHENGTANG INSTITUTE OF NATURAL MEDICATION CO., LTD. (CN) | 2021-07-08 | — | — | US | disclosed |
| WO-2020043129-A1 | LINKER CONTAINING ARYLNITRO, ANTIBODY-DRUG CONJUGATE CONTAINING LINKER AND USE OF LINKER | 中国人民解放军军事科学院军事医学研究院 | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210205464-A1 | Linker Containing Arylnitro, Antibody-Drug Conjugate Containing Linker and Use of Linker | BCR, FCGRT, ERBB2 | MMP1 1952/4885MMP2 2408/4885MMP9 2103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.